RNLXUSD
Renalytix Plc
A maker of artificial-intelligence diagnostic tests for kidney disease, Renalytix sells KidneyIntelX, a blood-based test that helps doctors predict which patients with early kidney disease are likely to progress to kidney failure. The company was formed in 2018 as a spinoff of the Mount Sinai Health System in New York, which remains a key partner, and is headquartered in London. Its name blends "renal" (the medical term for the kidneys) with "tix," a nod to the analytics and technology behind its tests.
ADRUnderlying: RNLXUSDCUSIP: 75973T101HealthcareGB1 holder
American Depositary Shares, each representing ordinary shares of Renalytix plc
Total Value
$7.74M
Total Shares
385.8K
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
